Capricorn Venture Partners makes first investment from its Capricorn Sustainable Chemistry Fund and completes ViroVetís series A funding

Leuven, Belgium: 6 October 2017 - Capricorn Venture Partners is pleased to announce the first investment for its Capricorn Sustainable Chemistry Fund (CSCF). The fund has invested in ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock. This investment concludes the second closing of ViroVet's series A financing round, in which they raised another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.

ViroVet pioneers in developing novel and innovative vaccines based on a unique proprietary technology platform that has the potential to produce vaccines faster and more cost-effectively. These vaccines are tailor-made to maximize efficacy and minimize safety concerns. In addition, the vaccines are thermostable thereby removing any cold-chain requirement. Earlier this year, ViroVet and GALVmed entered into a collaboration to develop novel vaccines for sheep and goats. The company also develops fast-acting antiviral drugs that are critical to the effective control and treatment of respiratory diseases of cattle and swine, thereby reducing secondary bacterial infections and the associated use of antibiotics.

The objective of the Capricorn Sustainable Chemistry Fund is to create shareholder value through financial return combined with the Sustainability Impact of the planned investments. The ViroVet investment contributes to realising the United Nation's Sustainable Development Goals, in particular Goal nrs. 2 and 3, which concern zero hunger and good health and wellbeing. Over 70 percent of human diseases originate in animals, so healthy animals contribute to healthy people and sustainable food production. In this context, ViroVet vaccines contribute to improving animal health by making animal production more efficient and sustainable, and in preventing and controlling diseases which threaten animal production, public health and trade.

More info on the press release or on ViroVet's website.  


Next > Ghentís industrial Internet of Things company, Sensolus, raises Ä 2.75 million

Previous > PacBio and Bluebee launch de novo genome assembly pipeline on the Bluebee analysis platform